Current report

according to ASF Regulation no. 5/2018

Report date:	**26.08.2026**
Name of issuer:	Farmaceutica REMEDIA SA
Registered office:	Deva, no. 2, Nicolae Bălcescu Blvd
Tel/ fax no:	+40 254 22 32 60 / +40 254 22 61 97
ORC no:	2115198
Trade Registry no:	J1991000700203
Subscribed and paid-in capital:	LEI 9.548.082
Regulated market:	Bucharest Stock Exchange, Standard Category

Important events to report:

RELEASE

The Board of Administrators of Farmaceutica REMEDIA SA informs that the Report for the 1st Semester of 2026 - the full version - is available on its own website https://corporate.remedia.ro/en/investor-relationship/financial-information/ and in the link from the IRIS platform, below.

During 01.01.2026 – 30.06.2026, Farmaceutica REMEDIA SA recorded the following consolidated financial results:

Crt. No.	Indicator	Realisations Jan-June 2026 (Lei)	Realisations Jan-June 2025 (Lei)**	Evolution 2026/2025 (%)
1.	Net sales of goods *	341.980.070	362.434.169	-5,64%
2.	Other operating revenues	3.965.585	5.647.594	-29,78%
3.	Total operating income	345.945.655	368.081.762	-6,01%
4.	Total operational costs *	344.167.695	359.914.258	-4,38%
5.	Operating result	1.777.960	8.167.504	-78,23%
6.	Financial result	1.037.499	674.396	53,84%
7.	Gross result	2.815.459	8.841.900	-68,16%

* Including trade discounts granted/received

The economic - financial indicators on 30.06.2026 are presented in the following table:

LIQUIDITY AND WORKING CAPITAL	**Farmaceutica REMEDIA SA**	**Farmaceutica REMEDIA Distribution & Logistics SRL**
Current liquidity (Current assets / Current debts)	3,07	1,05
Current assets	20.737.378	273.319.154

Current debts	6.753.456	260.896.206
Degree of indebtedness (Borrowed capital / Equity x 100)	0	0%
Borrowed capital	0	0
Equity	56.207.959	18.652.922
Turnover speed for client debit items (Average customer balance /turnover *180)	141 days	99 days
Average customer balance	2.754.543	190.126.316
Net turnover	3.527.879	343.968.762
Turnover speed of stocks (average stock/ net COGS)*180	486 days	32 days
Average stock	967.199	56.672.529
COGS net	358.273	316.205.786

*including financial leasing

Notes:

1) **Current liquidity** – the indicator level reflects a good payment capacity, therefore a reduced risk for creditors in case of FR and FRDL, certifying that the companies are able to cover their short-term debts based on receivables and cash availabilities.

2) **Degree of indebtedness** expresses the effectiveness of credit risk management, indicating potential financing, liquidity problems, with influences in honouring the assumed commitments. In the case of FR and FRDL there is no risk at all. In the calculation of this indicator, the borrowed capital comprises both bank credits, and financial leasing debts.

3) **Turnover speed for client debit items** expresses company effectiveness in collecting its receivables, respectively the number of days until the date on which debtors pay their debts to the company. Considering the dynamics of sales and the specifics of receivables in the distribution of medicines, we consider that the value of the indicator is normal for the companies from the group, under the given conditions.

4) The value of the indicator **No. of days of storage** can be regarded as falling within the scope of the business's specific operations, being influenced, in the case of FR, by the high level of stock represented by the BD Rowa robot. This is purchased exclusively on the basis of a firm order and an accepted quotation.

Chairman of the Board of Administrators,

„TARUS" – Valentin Norbert TARUS e.U.